Clinical vignette in antiretroviral therapy: Jaundice

Journal of the International Association of Physicians in AIDS Care

Volumn 2, Issue 4, 2003, Pages 133-139

  Zell, Steven C ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

adverse drug effect; antiretroviral; bilirubin; HIV 1; jaundice

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; JAUNDICE; LIVER DISEASE; LIVER FUNCTION TEST; MALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HIV-1; HUMANS; JAUNDICE; LIVER DISEASES; LIVER FUNCTION TESTS; MALE;

EID: 2342567760     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/154510970300200402     Document Type: Article

References (14)

1. Weisiger RA. Laboratory tests in liver disease and the approach to the patient with abnormal tests. In: Goldman L, Bennett J, eds. Cecil Textbook of Medicine 21st ed. Philadelphia: WB Saunders ; 2000: 757-779.
2. Chung R, Sherman K. Hepatic and hepatobiliary diseases. In: Dolin R, Masur H, Saag M, eds. AIDS Therapy 2nd ed. New York: Churchill Livingstone ; 2003: 902-920.
3. Talal A, Dieterich D. Gastrointestinal and hepatic manifestations of HIV infection. In: Sande M, Volberding P, eds. The Medical Management of AIDS 6th ed. Philadelphia: WB Saunders ; 1999: 195-216.
4. Cello JP. Acquired immunodeficiency s (Pubitemid 19121252)
5. Nash JA, Cohen SA. Gallbladder and biliary tract disease in AIDS. Gastroenterol Clin North Am 1997 ; 26 (2). 323-335. (Pubitemid 27279892)
6. Cappell MS, Schwartz MS, Biempica L. Clinical utility of liver biopsy in patients with serum antibodies to the human immunodeficiency virus. Am J Med 1990 ; 88 (2). 123-130. (Pubitemid 20051782)
7. Cavicchi M, Pialoux G, Carnot F, et al. Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated serum levels of alkaline phosphatase or gamma-glutamyl transferase. Clin Infect Dis 1995 ; 20 (3). 606-610.
8. O'Mara EM, Mummaneni V, Burchell B, et al. Relationship between uridine diphosphate-glucuronsyl transferase (UDP-GT) 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2000. Toronto, Ontario, Canada. (Abstract 1645).
9. Dieterich DT, Fischl M, Sepulveda G. The safety/efficacy of protease inhibitors (PIs) in hepatitis C (HCV) co-infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27-30, 2002. San Diego, California. (Abstract H-1729).
10. Badaro R, DeJesus E, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16 week results from BMS AI424-045. 2nd IAS Conference on HIV Pathogensis and Treatment. July 13-16, 2003. Paris, France. (Abstract 118).
11. Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002 ; 29 (4). 340-345. (Pubitemid 34288886)
12. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002 ; 35 (1). 182-189. (Pubitemid 34032559)
13. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000 ; 283 (1). 74-80. (Pubitemid 30038386)
14. Reisler R, Liou S, Servoss J, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. 1st IAS Conference on HIV Pathogenesis and Treatment. July 8-11, 2001. Buenos Aires, Argentina. (Abstract 43).